Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the eastern cooperative oncology group

Robert Dreicer, Shuli Li, Judith Manola, Naomi B. Haas, Bruce J. Roth, George Wilding

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

BACKGROUND. Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS-247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen. METHODS. Forty-five patients with advanced urothelial carcinoma were treated with BMS-247550 40 mg/m2 over 3 hours intravenously on Day 1 of a 21-day cycle and continued therapy until progression or unacceptable toxicity. RESULTS. Five patients obtained an objective partial response (PR) among the 42 eligible patients for an overall response rate of 11.9% (90% confidence interval [5.3%, 26.5%]). Median overall survival of the group was 8 months. Toxicity was moderate with granulocytopenia, fatigue, and sensory neuropathy being the most common side effects noted. CONCLUSIONS. BMS-247550 (ixabepilone) has very modest activity as a second-line therapy for advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and sensory neuropathy was common.

Original languageEnglish
Pages (from-to)759-763
Number of pages5
JournalCancer
Volume110
Issue number4
DOIs
StatePublished - Aug 15 2007

Keywords

  • Ixabepilone
  • Phase 2 trial
  • Urothelial carcinoma

Fingerprint Dive into the research topics of 'Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): A trial of the eastern cooperative oncology group'. Together they form a unique fingerprint.

Cite this